等待開盤 09-24 09:30:00 美东时间
-1.240
-1.57%
Happy Belly Food Group ( ($TSE:HBFG) ) has issued an announcement. Happy Belly ...
09-23 02:45
Brunswick’s (BC) chief executive and executive chairman David Foulkes announced his retirement, effective at the end of this year after two decades at the marine manufacturer. Aine Denari, currently s...
09-21 21:33
Brunswick (BC) chief executive officer and executive chairman David Foulkes will retire at the end of 2026 after eight years as CEO. Aine Denari, currently president of Navico Group and Brunswick’s ch...
09-21 21:18
Brunswick Corporation announced that CEO and Board Chairman David Foulkes will retire at the end of 2026. Aine Denari, currently Executive Vice President and President of Navico Group, has been appointed CEO effective January 1, 2027. David Everitt, Lead Independent Director, will become Non-Executive Chairman on the same date. Foulkes praised Denari's leadership and expressed confidence in her ability to lead the company forward. Denari emphasiz...
09-21 12:00
The latest update is out from AIS Resources ( ($TSE:AIS) ). A.I.S. Resources ha...
09-16 23:44
Brunswick Corporation showcased strong market momentum at the 2026 Cannes Yachting Festival, highlighted by the successful launch of the Navan C38, robust dealer demand, a record 67% outboard engine share for Mercury Marine, and a strategic partnership with Elettromedia to enhance integrated boating experiences.
09-15 10:35
<p>Canadian businesses are facing rising debt levels and increased financial stress, according to Equifax Canada's Q2 2026 report. Average commercial debt per business rose 7.3% year-over-year to $30,581, while the 60+ day delinquency rate on financial credit products reached 4.0%, up 19.7% year-over-year. Trade tariffs and economic uncertainty are adding pressure, with high-risk businesses and young companies seeing the sharpest debt growth. Des...
09-14 10:00
DuPont de Nemours (DD), Chemours (CC) and Corteva (CTVA) agreed to pay $455 million to settle claims involving PFAS contamination in North Carolina, including discharges tied to the Fayetteville Works...
09-10 19:48
HUTCHMED announced the conditional approval of fanregratinib (ATLED®) by China's NMPA for treating advanced FGFR2-altered intrahepatic cholangiocarcinoma (ICC) in adults who have received prior therapy. The approval is supported by Phase II trial data showing an objective response rate (ORR) of 42.5%, median progression-free survival (PFS) of 6.9 months, and median overall survival (OS) of 16.6 months. ATLED® is a potent, selective oral inhibitor...
08-28 00:00